BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Datamonitor Healthcare Oncology Disease Analysis: Triple-Negative Breast Cancer

March 31, 2021

Triple-negative breast cancer (TNBC) is a relatively rare breast cancer subtype. It is characterized by the absence of estrogen and progesterone receptors, and does not involve the overexpression of HER2. TNBC is associated with poor prognosis, a high risk of local recurrence, and poor disease-free and cancer-specific survival. It accounts for roughly 14% of breast cancers.

Worldwide, breast cancer is the second most common cancer and the fifth leading cause of cancer-related deaths regardless of gender. In the US, breast cancer is the most common cancer in women and the fourth leading cause of cancer-related deaths, regardless of gender, behind lung cancer, colorectal cancer, and pancreatic cancer.

The TNBC market will experience rapid growth over the next 10 years across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK). The primary drivers for this growth are the approval and subsequent uptake of new targeted therapies and immunotherapies. The market for triple-negative breast cancer is also becoming increasingly segmented by biomarker status, creating fierce competition among both approved and pipeline therapies for small patient populations.

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered: Breast Cancer
Back to the top Back to the top